LeMaitre Vascular
LMAT
189 hedge funds and large institutions have $971M invested in LeMaitre Vascular in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 72 increasing their positions, 61 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 61
10% more capital invested
Capital invested by funds: $879M → $971M (+$92.1M)
6% more funds holding
Funds holding: 179 → 189 (+10)
0.59% less ownership
Funds ownership: 87.86% → 87.27% (-0.59%)
Top Buyers
Top Sellers
| 1 |
SCA
Summit Creek Advisors
Minneapolis,
Minnesota
|
-$6.38M |
| 2 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
-$3.89M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.2M |
| 4 |
Goldman Sachs
New York
|
-$2.01M |
| 5 |
BG
Bahl & Gaynor
Cincinnati,
Ohio
|
-$1.95M |
LMAT Hedge Fund Activity: Q3 2022 in Review
189 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in LeMaitre Vascular (LMAT) for Q3 2022, worth a combined $971M — up 10% from $879M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LMAT positions and 13 closed out — a net gain of 11 holders — while 72 added to existing stakes and 61 trimmed.
The largest buyer was VOYA Investment Management, adding an estimated $3.21M. The largest seller was Summit Creek Advisors, cutting an estimated $6.38M.
- 189 institutional investors held LeMaitre Vascular (LMAT) as of Q3 2022, up from 179 in Q2 2022.
- Funds reported $971M of LeMaitre Vascular stock for Q3 2022, up 10% quarter-over-quarter.
- 24 funds opened new LeMaitre Vascular positions in Q3 2022 and 13 closed out, a net change of +11 holders.
- The largest LeMaitre Vascular buyer in Q3 2022 was VOYA Investment Management, an estimated $3.21M added.
- The largest LeMaitre Vascular seller in Q3 2022 was Summit Creek Advisors, an estimated $6.38M sold.
Based on aggregated 13F filings for Q3 2022.